Replimune to Present at 2024 ASCO Annual Meeting

Replimune Group Inc. (NASDAQ: REPL), a clinical-stage biotechnology company specializing in oncolytic immunotherapies, announced its participation in the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, scheduled from May 31 to June 4, 2024. The company will present multiple studies, including two abstracts selected for oral presentations and additional data in three trial-in-progress poster sessions.

The first oral presentation will feature updated 12-month data from the IGNYTE clinical trial, focusing on the efficacy and safety of RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with anti-PD-1 resistant melanoma. This session will provide a comparison between the 12-month data, with a cutoff date of March 8, 2024, and the previously disclosed 6-month results. The detailed results by independent central review are anticipated in the second quarter of 2024. This presentation will be part of the Melanoma/Skin Cancers session on June 3, 2024, from 10:57 to 11:03 AM CDT.

The second oral presentation will explore the safety, efficacy, and biomarker outcomes from a Phase 1 study of RP2, alone or combined with nivolumab, in patients with advanced uveal melanoma. This presentation is scheduled for the same session on June 3, 2024, from 9:57 to 10:03 AM CDT.

Replimune will also present three trial-in-progress posters, highlighting ongoing research in various cancer treatments. One poster will discuss a Phase 3 study of vusolimogene oderparepvec combined with nivolumab versus physician’s choice treatments in advanced melanoma patients who have progressed on anti-PD-1 and anti-CTLA-4 therapies. This session will occur on June 1, 2024, from 1:30 to 4:30 PM CDT in Hall A.

Another poster will present an open-label, multicenter study of RP2 in combination with atezolizumab and bevacizumab for patients with locally advanced unresectable or metastatic hepatocellular carcinoma. This study aims to evaluate the combination's efficacy as a second-line systemic therapy. This poster session is also scheduled for June 1, 2024, from 1:30 to 4:30 PM CDT in Hall A.

The final trial-in-progress poster will describe a Phase 1/2 study of vusolimogene oderparepvec in primary melanoma to reduce the risk of sentinel lymph node metastasis. This session will likewise be held on June 1, 2024, from 1:30 to 4:30 PM CDT in Hall A.

RP1, Replimune's lead product candidate, is engineered from a proprietary herpes simplex virus strain and armed with a fusogenic protein and GM-CSF, designed to enhance tumor killing, immunogenicity of tumor cell death, and systemic anti-tumor immune response activation. RP2 builds on this platform by additionally expressing an anti-CTLA-4 antibody-like molecule, aiming to focus immune response efficacy on tumors while minimizing off-target toxicity.

Founded in 2015 and based in Woburn, Massachusetts, Replimune aims to revolutionize cancer treatment with its innovative portfolio of oncolytic immunotherapies. Their RPx platform, built on a potent HSV-1 backbone, is designed to induce immunogenic cell death and systemic anti-tumor immunity. The company's products are envisioned to work synergistically with existing and experimental cancer treatments, offering versatility in therapeutic application.

Replimune's participation in the 2024 ASCO Annual Meeting underscores its commitment to advancing its clinical trials and developing novel cancer therapies. The company remains hopeful that the outcomes from these studies will contribute significantly to the field of oncology and improve treatment options for cancer patients worldwide.